Company

UniQure N.V.

UniQure N.V. is an Amsterdam-based gene therapy company developing AAV-based treatments for severe genetic disorders.

About

Headquartered in Amsterdam, Netherlands, UniQure N.V. develops gene therapies for severe genetic disorders using its proprietary AAV platform. Its core programs are AMT-130 for Huntington's disease and AMT-260 for refractory Mesial Temporal Lobe Epilepsy. In September 2025, UniQure secured a USD 175 million non-dilutive senior secured term loan facility from Hercules Capital to refinance existing debt and fund the anticipated U.S. commercial launch of AMT-130 in 2026.

2Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in